Policy & Regulation
Arctic Vision enrols first patient in ARVN003 phase III clinical study
5 July 2022 -

Arctic Vision, a China-based biotech company, announced on Monday that it has enrolled the first patient in a phase III clinical study assessing ARVN003, a proprietary pilocarpine formulation using its micro dosing platform Optejet, as a treatment to temporarily improve vision in adults with presbyopia in China.

The Phase III study, a double-masked, placebo-controlled, randomised, and multicentre trial, is to assess the efficacy and safety of the product in achieving temporary improvement of vision in adults with presbyopia. It is the first clinical trial approved in China for presbyopia drugs and the company's study represents the first patient enrolment in a Phase III clinical trial for presbyopia drugs in China. Presbyopia is a physiological condition that makes it difficult to read and work in near distance.

The company received an exclusive license in August 2020 for the development and commercialisation of ARVN003 (MicroLine) in Greater China and South Korea from United States-based Eyenovia.

Login
Username:

Password: